DESIGN: Mortality within the Swiss HIV Cohort Study for the years 1990-2001 was compared with the mortality of the general Swiss population. METHODS: Standardized mortality ratios (SMR) and life tables were calculated for strata defined by combinations of gender and HIV transmission group. The effect of dropouts was investigated with a sensitivity analysis and by analysing CD4 cell counts before dropout. RESULTS: During the study period 10 977 individuals had at least one cohort visit with a median observation time of 46 months. A total of 3630 patients died and 2290 dropped out. SMR decreased from 79.3 [95% confidence interval (CI), 77.2-81.5] before the introduction of highly active antiretroviral treatment (HAART) in 1996 to 15.3 (95% CI, 14.2-16.4) thereafter. For persons who acquired HIV infection by injecting drug use (IDUs), the SMR decreased from 98.2 (95% CI, 94.9-103.5) to 40.9 (95% CI, 37.0-44.8) after 1996; for all other HIV transmission groups the SMR decreased from 69.2 (95% CI, 66.9-71.6) to 9.4 (95% CI, 8.5-10.4). Thus, IDUs had significantly lower survival in comparison with other patient groups after 1996. Patients who had started HAART during the time period in which this treatment was available, had even lower SMRs. CONCLUSIONS: Although overall survival has improved considerably since the introduction of HAART, cohort life expectancy remains below that of the Swiss population. We noted, however, substantial differences in mortality among subgroups, and the results indicate that the additional risk related to injection drug use before 1996 had been masked by HIV-associated mortality.
DESIGN: Mortality within the Swiss HIV Cohort Study for the years 1990-2001 was compared with the mortality of the general Swiss population. METHODS: Standardized mortality ratios (SMR) and life tables were calculated for strata defined by combinations of gender and HIV transmission group. The effect of dropouts was investigated with a sensitivity analysis and by analysing CD4 cell counts before dropout. RESULTS: During the study period 10 977 individuals had at least one cohort visit with a median observation time of 46 months. A total of 3630 patients died and 2290 dropped out. SMR decreased from 79.3 [95% confidence interval (CI), 77.2-81.5] before the introduction of highly active antiretroviral treatment (HAART) in 1996 to 15.3 (95% CI, 14.2-16.4) thereafter. For persons who acquired HIV infection by injecting drug use (IDUs), the SMR decreased from 98.2 (95% CI, 94.9-103.5) to 40.9 (95% CI, 37.0-44.8) after 1996; for all other HIV transmission groups the SMR decreased from 69.2 (95% CI, 66.9-71.6) to 9.4 (95% CI, 8.5-10.4). Thus, IDUs had significantly lower survival in comparison with other patient groups after 1996. Patients who had started HAART during the time period in which this treatment was available, had even lower SMRs. CONCLUSIONS: Although overall survival has improved considerably since the introduction of HAART, cohort life expectancy remains below that of the Swiss population. We noted, however, substantial differences in mortality among subgroups, and the results indicate that the additional risk related to injection drug use before 1996 had been masked by HIV-associated mortality.
Authors: Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: M-J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Andrea Krusi; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Debbie M Cheng; David Nunes; Howard Libman; John Vidaver; Julie K Alperen; Richard Saitz; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2007-03-31 Impact factor: 3.455
Authors: C Lewden; E Jougla; A Alioum; G Pavillon; L Lièvre; P Morlat; D Salmon; T May; G Chêne; D Costagliola Journal: Epidemiol Infect Date: 2006-05-11 Impact factor: 2.451
Authors: Marcel Zwahlen; Ross Harris; Margaret May; Robert Hogg; Dominique Costagliola; Frank de Wolf; John Gill; Gerd Fätkenheuer; Charlotte Lewden; Mike Saag; Sholmo Staszewski; Antonella d'Arminio Monforte; Jordi Casabona; Fiona Lampe; Amy Justice; Viktor von Wyl; Matthias Egger Journal: Int J Epidemiol Date: 2009-10-09 Impact factor: 7.196
Authors: Audrey L French; Susan H Gawel; Ronald Hershow; Lorie Benning; Nancy A Hessol; Alexandra M Levine; Kathryn Anastos; Michael Augenbraun; Mardge H Cohen Journal: J Acquir Immune Defic Syndr Date: 2009-08-01 Impact factor: 3.731
Authors: Alexander Y Walley; Debbie M Cheng; Howard Libman; David Nunes; C Robert Horsburgh; Richard Saitz; Jeffrey H Samet Journal: AIDS Date: 2008-01-30 Impact factor: 4.177
Authors: Martin W G Brinkhof; Andrew Boulle; Ralf Weigel; Eugène Messou; Colin Mathers; Catherine Orrell; François Dabis; Margaret Pascoe; Matthias Egger Journal: PLoS Med Date: 2009-04-28 Impact factor: 11.069